Enlivex Therapeutics Ltd (ENLV)
$1.54
+0.02
(+1.32%)▲
Live
Performance
- $1.49$1.60$1.54
3.25%
Downside
Day's Volatility :6.82%
Upside
3.69%
- $1.15$4.59$1.54
25.32%
Downside
52 Weeks Volatility :74.95%
Upside
66.45%
Returns
| Period | Enlivex Therapeutics Ltd | Index (Russel 2000) |
|---|---|---|
3 Months | 10.95% | 0.0% |
6 Months | 19.69% | 0.0% |
1 Year | 15.15% | 0.0% |
3 Years | -82.63% | -23.0% |
Highlights
Market Capitalization | 34.9M |
Book Value | $1.37 |
Earnings Per Share (EPS) | -1.18 |
Wall Street Target Price | 9.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -27.46% |
Return On Equity TTM | -61.17% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -17.9M |
Diluted Eps TTM | -1.18 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.67 |
EPS Estimate Next Year | -0.58 |
EPS Estimate Current Quarter | -0.22 |
EPS Estimate Next Quarter | -0.19 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 516.88%
Technicals Summary
Sell
Neutral
Buy
Enlivex Therapeutics Ltd is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Enlivex Therapeutics Ltd | 2.7% | 19.69% | 15.15% | -82.63% | -82.08% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Enlivex Therapeutics Ltd | NA | NA | NA | -0.67 | -0.61 | -0.27 | NA | 1.37 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Enlivex Therapeutics Ltd | Buy | $34.9M | -82.08% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Enlivex Therapeutics Ltd
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 72.0%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 127.4%
Institutional Holdings
Armistice Capital, LLC
7.94%Morgan Stanley - Brokerage Accounts
1.14%Renaissance Technologies Corp
0.33%XTX Topco Ltd
0.12%Goldman Sachs Group Inc
0.05%Geode Capital Management, LLC
0.05%
Company Information
enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib clinical trial in patients with severe sepsis; that is in investigator-initiated phase ii clinical trial for the treatment of covid-19 patients in severe and critical conditions; and which is in phase iia clinical trial for the prevention of graft versus host disease in allogeneic hematopoietic stem cell transplants (hsct) patients. the company is also developing allocetra for the prevention of complications associated with bone marrow transplantations and/or hsct, and acute multiple organ failure. it also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor t-cell therapy and therapies targeting t-cell re
Organization | Enlivex Therapeutics Ltd |
Employees | 0 |
CEO | Mr. Shai Novik M.B.A. |
Industry | Biotechnology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$1.54
+1.32%
Invesco Bulletshares 2025 Hi
$1.54
+1.32%
Schwab International Dividend Equity Etf
$1.54
+1.32%
Blockchain Coinvestors Acquisition Corp.
$1.54
+1.32%
Allgiant Travel Company
$1.54
+1.32%
Rogers Corp
$1.54
+1.32%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$1.54
+1.32%
Iheartmedia
$1.54
+1.32%
Lightpath Technologies Inc
$1.54
+1.32%